Agile Therapeutics Inc (NASDAQ:AGRX) – William Blair issued their Q1 2019 earnings per share (EPS) estimates for shares of Agile Therapeutics in a research report issued to clients and investors on Wednesday, March 13th. William Blair analyst T. Lugo anticipates that the specialty pharmaceutical company will earn ($0.10) per share for the quarter. William Blair also issued estimates for Agile Therapeutics’ Q2 2019 earnings at ($0.09) EPS, Q3 2019 earnings at ($0.08) EPS, Q4 2019 earnings at ($0.08) EPS, FY2019 earnings at ($0.34) EPS and FY2020 earnings at $0.11 EPS.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Tuesday, March 12th. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.04.

Other research analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Agile Therapeutics in a research report on Friday, January 11th. Maxim Group began coverage on Agile Therapeutics in a research note on Thursday, November 29th. They issued a “buy” rating and a $3.00 price target on the stock. Finally, ValuEngine raised shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a report on Monday.

NASDAQ AGRX opened at $1.62 on Friday. Agile Therapeutics has a 52-week low of $0.23 and a 52-week high of $3.44. The firm has a market cap of $57.41 million, a PE ratio of -2.79 and a beta of 0.36.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. lifted its stake in Agile Therapeutics by 15.7% in the 4th quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock worth $77,000 after purchasing an additional 18,038 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Agile Therapeutics by 24.0% in the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 44,639 shares during the period. Acadian Asset Management LLC lifted its holdings in Agile Therapeutics by 260.7% during the 4th quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 226,255 shares in the last quarter. Fosun International Ltd acquired a new stake in shares of Agile Therapeutics in the third quarter valued at $180,000. Finally, Renaissance Technologies LLC increased its position in shares of Agile Therapeutics by 54.3% in the 3rd quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock valued at $449,000 after purchasing an additional 430,907 shares during the last quarter. 42.15% of the stock is owned by institutional investors.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Read More: Can systematic risk be avoided?

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.